Core Viewpoint - Yiming Pharmaceutical (002826) is undergoing a board restructuring following the completion of its third board term, marking the first adjustment since the entry of 58.com founder Yao Jinbo into the company [1][4] Group 1: Board Restructuring - The new fourth board will consist of 7 directors, down from 8, including 3 independent directors, 3 non-independent directors, and 1 employee director [2] - All independent and non-independent directors from the previous board will be replaced [2] - Candidates for non-independent directors include Fu Lihua, Huang Lingyi, and Yao Yan, with backgrounds in management and education technology [2][3] Group 2: Shareholding Changes - Beijing Fuhao is expected to secure all non-independent director positions, indicating a new era under Yao Jinbo's leadership [4] - In May, Beijing Fuhao signed a share transfer agreement to acquire 23% of Yiming Pharmaceutical's shares from the former controlling shareholder, Gao Fan, at a price of 15.10 yuan per share, totaling 662 million yuan [4] Group 3: Company Overview - Yiming Pharmaceutical primarily engages in drug sales and promotion services, with a focus on cardiovascular and diabetes-related products [4] - The company's core product, Miglitol tablets, holds a leading market share in the domestic Miglitol market for type 2 diabetes treatment [4] - The company has maintained stable annual revenues of approximately 650 million yuan over the past two years [4] Group 4: Market Implications - Yao Jinbo's entry into the pharmaceutical industry has generated significant market interest regarding the potential resources and advantages he may bring to the company [5] - Beijing Fuhao has expressed intentions to leverage its strengths in investment management and industry planning to empower the company's business development [5]

Group 1 - The company held its 27th temporary board meeting on September 2, 2025, to conduct the board member election process as the current term has expired [1][2] - The fourth board will consist of 7 members, including 3 independent directors, 3 non-independent directors, and 1 employee director [1] - The board proposed the election of three non-independent directors: Fu Lihua, Huang Lingyi, and Yao Yan, with unanimous approval from all 7 attending board members [2][3] Group 2 - The board also proposed the election of three independent directors: He Deming, Chen Yan, and Wang Guangying, with unanimous approval from all 7 attending board members [3][9] - The independent director candidates have met the qualifications required by the Shenzhen Stock Exchange and will be submitted for approval at the upcoming shareholder meeting [3][9] - The fourth independent directors' term will last for three years starting from the date of election approval at the shareholder meeting [3][9] Group 3 - The company plans to hold the 2025 second temporary shareholder meeting on September 19, 2025, at 14:00 [4] - The meeting will include the election of the new board members using a cumulative voting system [4] - The resumes of the nominated candidates for both independent and non-independent directors are attached for reference [4][8]

Group 1 - The candidate, He Deming, has been nominated as an independent director for the fourth board of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and has confirmed understanding and agreement with the nomination [1] - The candidate declares that there are no relationships that could affect his independence and meets the qualifications required by relevant laws and regulations [1][2] - The candidate has passed the qualification review by the nomination committee of the company's third board and has no interests that could influence his independent performance [1][2] Group 2 - The candidate affirms compliance with the requirements of the Company Law of the People's Republic of China regarding eligibility to serve as a director [2] - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2] - The candidate confirms that serving as an independent director will not violate any relevant regulations, including those from the Central Commission for Discipline Inspection and the Ministry of Education [2][3] Group 3 - The candidate has no direct or indirect shareholding of more than 1% in the company or its major shareholders [5] - The candidate and immediate family members do not hold positions in the company or its subsidiaries [5][6] - The candidate has not been subject to any disqualifications or penalties by the China Securities Regulatory Commission or other regulatory bodies [7][8] Group 4 - The candidate commits to fulfilling the responsibilities of an independent director and ensuring that all statements and materials provided are true and complete [9][10] - The candidate will report any changes in eligibility to the board and will resign if any disqualifying conditions arise [9] - The candidate authorizes the company to disclose this declaration and related information to the Shenzhen Stock Exchange [10]

Group 1 - The company has nominated Chen Yan as a candidate for the independent director of its fourth board, and the nominee has agreed to this nomination [1] - The nomination was made after a thorough understanding of the nominee's professional background, education, qualifications, and any potential conflicts of interest [1] - The nominee has passed the qualification review by the company's third board nomination committee, confirming no close relationships that could affect independent performance [2] Group 2 - The nominee meets the qualifications and independence requirements set by relevant laws, regulations, and the Shenzhen Stock Exchange [2][3] - The nominee has participated in training and obtained relevant certification recognized by the stock exchange [2] - The nominee does not have any disqualifying conditions as per the Company Law of the People's Republic of China [2] Group 3 - The nominee has no significant business dealings with the company or its controlling shareholders [7] - The nominee has not been subject to any market entry bans by the China Securities Regulatory Commission [8] - The nominee has not received any public reprimands from the stock exchange in the last thirty-six months [8]

Group 1 - The candidate Chen Yan has been nominated as an independent director for the fourth board of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and has confirmed understanding and agreement with the nomination [1] - The candidate declares that there are no relationships that could affect independence and meets the qualifications required by relevant laws and regulations [1][2] - The candidate has passed the qualification review by the nomination committee of the company's third board and has no interests or relationships that could influence independent performance [1][2] Group 2 - The candidate affirms compliance with the requirements of the Company Law of the People's Republic of China regarding eligibility to serve as a director [2][3] - The candidate has participated in training and obtained relevant certification recognized by the stock exchange [2][3] - The candidate confirms that serving as an independent director will not violate any relevant regulations, including those from the Central Commission for Discipline Inspection and the Ministry of Education [2][3][4] Group 3 - The candidate has no direct or indirect shareholding of more than 1% in the company and is not among the top ten shareholders [5][6] - The candidate and immediate family members do not hold positions in the company or its subsidiaries [5][6] - The candidate has no significant business dealings with the company or its controlling shareholders [6][7] Group 4 - The candidate has not been subject to any disqualifications or penalties by the China Securities Regulatory Commission or the stock exchange [7][8] - The candidate has not been publicly reprimanded by the stock exchange in the last thirty-six months [8][9] - The candidate has not served as an independent director in more than three domestic listed companies [9][10]

Group 1 - The company, Yiming Pharmaceutical, announced the approval of multiple proposals during the 27th temporary meeting of its third board of directors, including the election of non-independent directors [2]

Group 1 - The company, Yiming Pharmaceutical (002826), announced that it will hold its second extraordinary general meeting of shareholders in 2025 on September 19 [1] - The agenda for the meeting includes the review of multiple proposals, including the election of non-independent directors to the board [1]

西藏易明西雅医药科技股份有限公司 独立董事候选人声明与承诺 声明人王广英作为西藏易明西雅医药科技股份有限公司第四届董事会独立 董事候选人，已充分了解并同意由提名人西藏易明西雅医药科技股份有限公司董 事会提名为西藏易明西雅医药科技股份有限公司（以下简称该公司）第四届董事 会独立董事候选人。现公开声明和保证，本人与该公司之间不存在任何影响本人 独立性的关系，且符合相关法律、行政法规、部门规章、规范性文件和深圳证券 交易所业务规则对独立董事候选人任职资格及独立性的要求，具体声明并承诺如 下事项： 如否，请详细说明：______________________________ 一、本人已经通过西藏易明西雅医药科技股份有限公司第三届董事会提名委 员会资格审查，提名人与本人不存在利害关系或者其他可能影响独立履职情形的 密切关系。 ☑ 是□否 如否，请详细说明：______________________________ 二、本人不存在《中华人民共和国公司法》第一百七十八条等规定不得担任 公司董事的情形。 ☑ 是□否 如否，请详细说明：______________________________ 三、本人符合中国证监会《上 ...

西藏易明西雅医药科技股份有限公司 独立董事提名人声明与承诺 提名人西藏易明西雅医药科技股份有限公司董事会现就提名何德明为西藏 易明西雅医药科技股份有限公司第四届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为西藏易明西雅医药科技股份有限公司第四届董事会独立 董事候选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况 后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性 文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具 体声明并承诺如下事项： 一、被提名人已经通过西藏易明西雅医药科技股份有限公司第三届董事会提 名委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑ 是□否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 ☑ 是□否 如否，请详细说明：______________________________ 三、被提名 ...

☑ 是□否 如否，请详细说明：______________________________ 西藏易明西雅医药科技股份有限公司 独立董事提名人声明与承诺 提名人西藏易明西雅医药科技股份有限公司董事会现就提名王广英为西藏 易明西雅医药科技股份有限公司第四届董事会独立董事候选人发表公开声明。被 提名人已书面同意作为西藏易明西雅医药科技股份有限公司第四届董事会独立 董事候选人（参见该独立董事候选人声明）。本次提名是在充分了解被提名人职 业、学历、职称、详细的工作经历、全部兼职、有无重大失信等不良记录等情况 后作出的，本提名人认为被提名人符合相关法律、行政法规、部门规章、规范性 文件和深圳证券交易所业务规则对独立董事候选人任职资格及独立性的要求，具 体声明并承诺如下事项： 一、被提名人已经通过西藏易明西雅医药科技股份有限公司第三届董事会提 名委员会资格审查，提名人与被提名人不存在利害关系或者其他可能影响独立履 职情形的密切关系。 ☑ 是□否 如否，请详细说明：______________________________ 二、被提名人不存在《中华人民共和国公司法》第一百七十八条等规定不得 担任公司董事的情形。 五、被提名 ...